<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02022527</url>
  </required_header>
  <id_info>
    <org_study_id>PEU2013</org_study_id>
    <nct_id>NCT02022527</nct_id>
  </id_info>
  <brief_title>Cost Effectiveness Analysis In Patients With Heart Valve Prosthesis</brief_title>
  <acronym>HVP</acronym>
  <official_title>Cost Effectiveness Analysis for Combination Of Aspirin And Warfarin Versus Warfarin Alone In Egyptian Patients With Heart Valve Prosthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacoeconomic Unit, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacoeconomic Unit, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combined Antiplatelet and Anticoagulant treatment decreased thrombus formation and
      overall mortality. Also the initiation of an efficacious early anticoagulation protocol is
      important because of its potential impact on the rate of early thromboembolic complications
      after mechanical valve implantation. An important question that remains to be answered is
      whether the combination would be cost effective than Warfarin alone, with a reduction in
      major bleeding. In addition, the knowledge about its cost-effectiveness has not yet been
      established in Egypt. The aim of this trial based economic evaluation is to conduct a
      cost-effectiveness analysis for combination of low-dose Aspirin and Warfarin versus Warfarin
      alone in prosthetic valve patients from the medical provider perspective specially that a
      misconception is still existed between the physicians in Egypt that the cost of complications
      is not worthy so our main aim is to test the cost of complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The measurements will be assessed:

      A- Number of patients improved during follow up:

        1. Demographic data

        2. Diagnosis

        3. Laboratory tests (CBC, Prothrombin Time, liver and renal function tests)

        4. Echocardiography profile

      B-Costs:

      Direct medical costs will be assessed directly from hospital's records and tender lists.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Valve Thrombosis</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Systemic Embolism,</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal intracranial hemorrhage</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major extra cranial hemorrhage,</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Complications Due to Heart Valve Prosthesis</condition>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Warfarin tablets adjusted according to international normalized ratio (INR) (2 for Aortic Valve Replacement &amp; 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and oral 75 mg Acetyl Salicylic Acid tablets daily long life.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin tablets adjusted according to INR (2 for Aortic Valve Replacement &amp; 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and placebo long life.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetyl Salicylic Acid</intervention_name>
    <arm_group_label>Combination</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Marevan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Aspirin)</intervention_name>
    <description>Sugar pill manufactured to mimic 75 mg Aspirin</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients operated in Ain Shams University Hospitals for aortic and/ or mitral valve
        replacement.

        Exclusion Criteria:

          -  Congenital blood disorders, Hemophilia.

          -  Advanced liver disease

          -  Advanced renal disease (dialysis patients)

          -  Aspirin sensitivity

          -  Autoimmune diseases

          -  Biological bioprosthesis valves

          -  Non-compliant &amp; Drop out patient

          -  Pregnant women

          -  Caucasians.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gihan H Elsisi, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmacoeconomic Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manal H Elhamamsy, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of pharmacy, Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed ME Mazar, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Central Administration for Pharmaceutical Affairs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gihan H Elsisi, Msc</last_name>
    <phone>+201227366018</phone>
    <email>gihan-elsisi@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manal H Elhamamsy, PhD</last_name>
    <phone>+201005257416</phone>
    <email>M_elhamamsy@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams University hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Hassouna, MD</last_name>
      <phone>+201223105271</phone>
    </contact>
    <investigator>
      <last_name>Basma Awad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://download.journals.elsevierhealth.com/pdfs/journals/2212-1099/PIIS2212109913000770.pdf</url>
    <description>Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt</description>
  </link>
  <reference>
    <citation>Mohamed H. Antithrombotic therapy in patients with prosthetic heart valves. Libyan J Med. 2009 Mar 1;4(1):54-6. doi: 10.4176/090115.</citation>
    <PMID>21483507</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>December 26, 2013</last_update_submitted>
  <last_update_submitted_qc>December 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pharmacoeconomic Unit, Egypt</investigator_affiliation>
    <investigator_full_name>Gihan Hamdy Elsisi</investigator_full_name>
    <investigator_title>Head of Pharmacoeconomic Unit</investigator_title>
  </responsible_party>
  <keyword>Cost-Effectiveness,</keyword>
  <keyword>Heart valve prosthesis</keyword>
  <keyword>Warfarin,</keyword>
  <keyword>Aspirin,</keyword>
  <keyword>Egypt</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

